Pub Date : 2025-10-01Epub Date: 2025-09-03DOI: 10.1177/10766294251374533
Tao Xie, Junyong Chen, Shuangshuang Wang, Qinghuan Zhang, Weiling Xia, Shiya Su, Xuehua Lin, Fengqiu Yang, Jian Deng, Xiaobin Li, Wen Su, Wenjun Ni
Purpose: The Gram-negative bacterium Aeromonas caviae is an important opportunistic facultative anaerobic pathogen. In the present study, we aimed to elucidate the whole-genome sequence of the multidrug-resistant (MDR) A. caviae strain AC1520, detailing its acquired antibiotic resistance genes (ARGs) and their genetic elements. Patients and Methods: The A. caviae strain AC1520 was isolated from a urine sample taken from a patient with urinary tract infection. Whole-genome sequencing was performed following strain identification and antimicrobial susceptibility testing. Overall, we identified ARGs, integrons, insertion sequences (IS), and transposons acquired by strain AC1520, systematically analyzing the genetic elements associated with these ARGs. Results: The A. caviae strain AC1520 contained a circular chromosome and a plasmid. Multilocus sequence typing revealed that this strain belonged to ST-1056. All ARGs within this strain were distributed on the circular chromosome. We identified two MDR regions: (1) IS common region 1 (ISCR1) and class 1 integron (IntI1) elements associated with aadA16, aac(6')-Ib-cr, catB3, qacE (two copies), sul1 (two copies), and blaPER-3; one gene cluster structure (IS6100-mphR(A)-mph(A)-mrx(A)-IS26); (2) Two IntI1 elements, linked to ant(2'')-Ia, blaOXA-10, aadA2b, aph(3'')-Ib, aph(6)-Id, ARR-2, aac(6')-Ib3, dfrA1, qacE, and sul1. Notably, these two MDR regions were not only present in A. caviae but also in other bacteria, such as Aeromonas hydrophila, Aeromonas media, and Edwardsiella tarda. Conclusion: The A. caviae strain AC1520 with two separate MDR regions and 20 ARGs, conferring resistance to aminoglycoside, fluoroquinolone, phenicol, sulfonamide, beta-lactam, macrolide, rifampicin, and trimethoprim, was identified in a hospital in China. Mobile genetic elements including TnAs1, ISCR1, ISAs25, IS6100, IS26, TnAs3, ISAs1, and Tn3, were found within the MDR region, which could play important roles in the global dissemination of these resistance genes.
{"title":"Whole-Genome Sequencing Analysis of the Multidrug-Resistant <i>Aeromonas caviae</i> Strain AC1520 Isolated from a Patient with Urinary Tract Infection.","authors":"Tao Xie, Junyong Chen, Shuangshuang Wang, Qinghuan Zhang, Weiling Xia, Shiya Su, Xuehua Lin, Fengqiu Yang, Jian Deng, Xiaobin Li, Wen Su, Wenjun Ni","doi":"10.1177/10766294251374533","DOIUrl":"10.1177/10766294251374533","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> The Gram-negative bacterium <i>Aeromonas caviae</i> is an important opportunistic facultative anaerobic pathogen. In the present study, we aimed to elucidate the whole-genome sequence of the multidrug-resistant (MDR) <i>A. caviae</i> strain AC1520, detailing its acquired antibiotic resistance genes (ARGs) and their genetic elements. <b><i>Patients and Methods:</i></b> The <i>A. caviae</i> strain AC1520 was isolated from a urine sample taken from a patient with urinary tract infection. Whole-genome sequencing was performed following strain identification and antimicrobial susceptibility testing. Overall, we identified ARGs, integrons, insertion sequences (IS), and transposons acquired by strain AC1520, systematically analyzing the genetic elements associated with these ARGs. <b><i>Results:</i></b> The <i>A. caviae</i> strain AC1520 contained a circular chromosome and a plasmid. Multilocus sequence typing revealed that this strain belonged to ST-1056. All ARGs within this strain were distributed on the circular chromosome. We identified two MDR regions: (1) IS common region 1 (IS<i>CR1</i>) and class 1 integron (Int<i>I1</i>) elements associated with <i>aadA16</i>, <i>aac(6')-Ib-cr</i>, <i>catB3</i>, <i>qacE</i> (two copies), <i>sul1</i> (two copies), and <i>bla<sub>PER-3</sub></i>; one gene cluster structure (IS<i>6100</i>-<i>mphR(A)</i>-<i>mph(A)</i>-<i>mrx(A)</i>-IS<i>26</i>); (2) Two Int<i>I1</i> elements, linked to <i>ant(2'')-Ia</i>, <i>bla<sub>OXA-10</sub></i>, <i>aadA2b</i>, <i>aph(3'')-Ib</i>, <i>aph(6)-Id</i>, <i>ARR-2, aac(6')-Ib3, dfrA1, qacE,</i> and <i>sul1</i>. Notably, these two MDR regions were not only present in <i>A. caviae</i> but also in other bacteria, such as <i>Aeromonas hydrophila</i>, <i>Aeromonas media</i>, and <i>Edwardsiella tarda</i>. <b><i>Conclusion:</i></b> The <i>A. caviae</i> strain AC1520 with two separate MDR regions and 20 ARGs, conferring resistance to aminoglycoside, fluoroquinolone, phenicol, sulfonamide, beta-lactam, macrolide, rifampicin, and trimethoprim, was identified in a hospital in China. Mobile genetic elements including Tn<i>As1</i>, IS<i>CR1</i>, IS<i>As25</i>, IS<i>6100</i>, IS<i>26</i>, Tn<i>As3</i>, IS<i>As1</i>, and Tn<i>3</i>, were found within the MDR region, which could play important roles in the global dissemination of these resistance genes.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"309-316"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Cefepime (FEP), a fourth-generation cephalosporin combined with tazobactam (TAZ), a β-lactamase inhibitor, is being developed by Wockhardt as a pharmacodynamically optimized fixed dose combination (FEP-2 g + TAZ-2 g) for the treatment of multidrug-resistant Gram-negative infections. To undertake an exposure-response analysis for establishing pharmacokinetic (PK)/pharmacodynamic (PD) targets, it is crucial to characterize the PK profile of compounds in surrogate compartments, such as plasma and lung, in clinically relevant animal infection models used to evaluate in vivo efficacy. In the current study, PKs of FEP and TAZ were assessed in plasma and in epithelial lining fluid (ELF) of neutropenic noninfected, lung-infected, and thigh-infected mice. Methods: Neutropenic mice were infected by intranasal or intramuscular administration of 106-107 colony-forming units per milliliter of Escherichia coli to develop infection in lung or thigh. Post 2 hours of infection, single doses of WCK 4282 at 25 + 25, 50 + 50, and 100 + 100 mg/kg were subcutaneously administered. Plasma and bronchoalveolar lavage fluid were collected up to 8 hours post-administration of doses. Results: The PK of FEP and TAZ in plasma/ELF in healthy and infected mice did not differ significantly. The plasma PK profiles of FEP and TAZ were linear and dose proportional with modest ELF penetrations in the neutropenic infected mice. The ELF exposures of FEP and TAZ were slightly lower in thigh-infected mice and higher in lung-infected mice when compared with healthy mice. Irrespective of health condition, the mean ELF/plasma area under the curve penetration ratio for FEP and TAZ was similar and comparable (0.42-0.43). Conclusion: The estimates of FEP and TAZ PK parameters estimated in the current study would help in PK-PD studies for the selection of doses for upcoming in vivo efficacy studies.
{"title":"Pharmacokinetics and Penetration of a Novel Pharmacodynamically Optimized, Carbapenem-Sparing Antibiotic, WCK 4282 (Cefepime/Tazobactam), into Epithelial Lining Fluid of Healthy, Lung-, and Thigh-Infected Neutropenic Mice.","authors":"Rajesh Chavan, Vineet Zope, Kiran Patil, Swapna Takalkar, Pavan Tayde, Kushal Umarkar, Ravindra Yeole, Sachin Bhagwat","doi":"10.1177/10766294251378228","DOIUrl":"10.1177/10766294251378228","url":null,"abstract":"<p><p><b><i>Objectives:</i></b> Cefepime (FEP), a fourth-generation cephalosporin combined with tazobactam (TAZ), a β-lactamase inhibitor, is being developed by Wockhardt as a pharmacodynamically optimized fixed dose combination (FEP-2 g + TAZ-2 g) for the treatment of multidrug-resistant Gram-negative infections. To undertake an exposure-response analysis for establishing pharmacokinetic (PK)/pharmacodynamic (PD) targets, it is crucial to characterize the PK profile of compounds in surrogate compartments, such as plasma and lung, in clinically relevant animal infection models used to evaluate <i>in vivo</i> efficacy. In the current study, PKs of FEP and TAZ were assessed in plasma and in epithelial lining fluid (ELF) of neutropenic noninfected, lung-infected, and thigh-infected mice. <b><i>Methods:</i></b> Neutropenic mice were infected by intranasal or intramuscular administration of 10<sup>6</sup>-10<sup>7</sup> colony-forming units per milliliter of <i>Escherichia coli</i> to develop infection in lung or thigh. Post 2 hours of infection, single doses of WCK 4282 at 25 + 25, 50 + 50, and 100 + 100 mg/kg were subcutaneously administered. Plasma and bronchoalveolar lavage fluid were collected up to 8 hours post-administration of doses. <b><i>Results:</i></b> The PK of FEP and TAZ in plasma/ELF in healthy and infected mice did not differ significantly. The plasma PK profiles of FEP and TAZ were linear and dose proportional with modest ELF penetrations in the neutropenic infected mice. The ELF exposures of FEP and TAZ were slightly lower in thigh-infected mice and higher in lung-infected mice when compared with healthy mice. Irrespective of health condition, the mean ELF/plasma area under the curve penetration ratio for FEP and TAZ was similar and comparable (0.42-0.43). <b><i>Conclusion:</i></b> The estimates of FEP and TAZ PK parameters estimated in the current study would help in PK-PD studies for the selection of doses for upcoming <i>in vivo</i> efficacy studies.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"338-344"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antimicrobial resistance (AMR) is one of the most important concerns in the world, occurring for both Gram-positive and Gram-negative bacteria. Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative bacterium belonging to the family of Enterobacteriaceae and also plays an important role in development of nosocomial infections. Three forms have emerged as a result of AMR including multi-drug resistant (MDR), extensively drug-resistant, and pan-drug-resistant. Nowadays, physicians cannot save most of the patients that suffer from MDR K. pneumoniae infections by typical antibiotics, so they should try other useful alternative treatments. Our aim in this review study was to search about the latest useful alternative methods against MDR K. pneumoniae infections. We collected some articles from PubMed, MEDLINE, and Google Scholar by the keywords of multi-drug-resistant K. pneumoniae, AMR, and alternative treatments, where finally 183 articles were selected. Also, inclusion criteria and exclusion criteria were identified separately. It was understood that there are novel therapeutic options against MDR K. pneumoniae infections, which include odilorhabdins, drug delivery systems, antibody drug conjugation treatments, nano-antibiotics, bacteriocins, probiotics, fecal transplant therapy, predatory bacteria, combined antibiotics, double-carbapenem therapy, synthetic lipopeptides, and phage therapy.
{"title":"Overcoming Multi-Drug-Resistant <i>Klebsiella pneumoniae</i> Infections.","authors":"Nastaran Javan, Reza Ghotaslou, Hossein Samadi Kafil, Mohammad Yousef Memar, Javid Sadeghi, Pardis Ghotaslou","doi":"10.1177/10766294251375937","DOIUrl":"10.1177/10766294251375937","url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) is one of the most important concerns in the world, occurring for both Gram-positive and Gram-negative bacteria. <i>Klebsiella pneumoniae</i> (<i>K. pneumoniae</i>) is a Gram-negative bacterium belonging to the family of Enterobacteriaceae and also plays an important role in development of nosocomial infections. Three forms have emerged as a result of AMR including multi-drug resistant (MDR), extensively drug-resistant, and pan-drug-resistant. Nowadays, physicians cannot save most of the patients that suffer from MDR <i>K. pneumoniae</i> infections by typical antibiotics, so they should try other useful alternative treatments. Our aim in this review study was to search about the latest useful alternative methods against MDR <i>K. pneumoniae</i> infections. We collected some articles from PubMed, MEDLINE, and Google Scholar by the keywords of multi-drug-resistant <i>K. pneumoniae</i>, AMR, and alternative treatments, where finally 183 articles were selected. Also, inclusion criteria and exclusion criteria were identified separately. It was understood that there are novel therapeutic options against MDR <i>K. pneumoniae</i> infections, which include odilorhabdins, drug delivery systems, antibody drug conjugation treatments, nano-antibiotics, bacteriocins, probiotics, fecal transplant therapy, predatory bacteria, combined antibiotics, double-carbapenem therapy, synthetic lipopeptides, and phage therapy.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"323-337"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In high-burden tuberculosis (TB) settings such as Iran, non-tuberculous mycobacteria (NTM) are increasingly identified among presumptive TB cases. However, their epidemiology and drug resistance patterns remain inadequately described. This study investigated the prevalence, species distribution, and antimicrobial susceptibility of NTM isolates from 3,000 clinical specimens collected from patients with presumptive TB at the Pasteur Institute of Iran between March 2022 and March 2023. Identification was performed through culture and sequencing of the 16S rDNA, rpoB, and hsp65 genes. Drug susceptibility testing (DST) was conducted using the broth microdilution method in accordance with Clinical and Laboratory Standards Institute guidelines. Among 145 acid-fast bacilli-positive cultures, 45 (31%) were identified as NTM. The predominant species were Mycobacterium fortuitum (51.1%) and M. simiae (40.0%), followed by less common isolates of M. abscessus, M. kansasii, and M. flavescens. The majority of NTM isolates (86.7%) originated from respiratory specimens. Phenotypic analyses revealed high resistance rates to first-line anti-TB drugs such as isoniazid and rifampicin, while susceptibility varied across fluoroquinolones, aminoglycosides, and sulfonamides. These findings underscore the importance of species-level identification and DST-guided therapy to improve the clinical management of NTM infections in TB-endemic regions.
{"title":"Molecular Epidemiology of Non-Tuberculous Mycobacteria Among Tuberculosis-Suspected Patients in Iran: Species Distribution and Drug Resistance.","authors":"Maryam Rahimi, Abbas Akhavan Sepahi, Fatemeh Sakhaee, Seyed Davar Siadat, Abolfazl Fateh","doi":"10.1177/10766294251375421","DOIUrl":"https://doi.org/10.1177/10766294251375421","url":null,"abstract":"<p><p>In high-burden tuberculosis (TB) settings such as Iran, non-tuberculous mycobacteria (NTM) are increasingly identified among presumptive TB cases. However, their epidemiology and drug resistance patterns remain inadequately described. This study investigated the prevalence, species distribution, and antimicrobial susceptibility of NTM isolates from 3,000 clinical specimens collected from patients with presumptive TB at the Pasteur Institute of Iran between March 2022 and March 2023. Identification was performed through culture and sequencing of the <i>16S rDNA</i>, <i>rpoB</i>, and <i>hsp65</i> genes. Drug susceptibility testing (DST) was conducted using the broth microdilution method in accordance with Clinical and Laboratory Standards Institute guidelines. Among 145 acid-fast bacilli-positive cultures, 45 (31%) were identified as NTM. The predominant species were <i>Mycobacterium fortuitum</i> (51.1%) and <i>M. simiae</i> (40.0%), followed by less common isolates of <i>M. abscessus</i>, <i>M. kansasii</i>, and <i>M. flavescens</i>. The majority of NTM isolates (86.7%) originated from respiratory specimens. Phenotypic analyses revealed high resistance rates to first-line anti-TB drugs such as isoniazid and rifampicin, while susceptibility varied across fluoroquinolones, aminoglycosides, and sulfonamides. These findings underscore the importance of species-level identification and DST-guided therapy to improve the clinical management of NTM infections in TB-endemic regions.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":"31 10","pages":"303-308"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Antimicrobial resistance is a critical global threat in resource-limited settings with underdeveloped laboratory capacity and stewardship programs. Intensive care unit (ICU) patients are at high risk for complicated urinary tract infections (cUTIs) caused by multidrug-resistant (MDR) uropathogens. Local resistance data are essential to guide empirical therapy and design effective stewardship interventions. Methods: We conducted a retrospective, cross-sectional study (March 2020-December 2022) of 127 adult ICU patients with cUTIs at a tertiary hospital in Tehran, Iran. Urine isolates were identified by standard phenotypic methods, and antimicrobial susceptibility testing (AST) was performed via disk diffusion following Clinical and Laboratory Standards Institute guidelines. Resistance phenotypes-extended-spectrum beta-lactamase (ESBL) production, carbapenem-resistant Enterobacteriaceae, vancomycin-resistant enterococci (VRE), difficult-to-treat Pseudomonas, and pan-drug-resistant (PDR) Acinetobacter baumannii-were defined using current breakpoints. Results:Escherichia coli (52.2%) and Klebsiella pneumoniae (26.9%) predominated. Among Enterobacterales, 60.4% produced ESBL and 30.2% were carbapenem resistant. VRE comprised all enterococcal isolates; PDR A. baumannii occurred in one case. No significant associations were found between resistance profiles and sepsis, septic shock, or mortality. Multivariable analysis identified heart failure (odds ratio [OR] 2.45; 95% confidence interval [CI] 1.15-5.21; p = 0.017) and longer ICU stay (OR 1.03 per day; 95% CI 1.01-1.05; p = 0.012) as independent predictors of MDR infection. Conclusions: We report an alarming burden of MDR uropathogens in Tehran ICUs, underscoring the need for tailored empirical-therapy guidelines, enhanced antimicrobial stewardship programs, and multicenter surveillance to curb resistance and improve patient outcomes.
背景:在实验室能力和管理规划不发达、资源有限的环境下,抗菌素耐药性是一个严重的全球威胁。重症监护病房(ICU)患者是由多药耐药(MDR)尿路病原体引起的复杂尿路感染(cUTIs)的高危人群。当地耐药性数据对于指导经验性治疗和设计有效的管理干预措施至关重要。方法:我们于2020年3月至2022年12月对伊朗德黑兰一家三级医院的127例cuti成人ICU患者进行了回顾性横断面研究。通过标准表型方法鉴定尿液分离物,并按照临床和实验室标准协会的指导方针通过磁盘扩散进行抗菌药敏试验(AST)。使用当前断点定义耐药表型-广谱β -内酰胺酶(ESBL)产生,碳青霉烯耐药肠杆菌科,万古霉素耐药肠球菌(VRE),难以治疗的假单胞菌和泛耐药(PDR)鲍曼不动杆菌。结果:以大肠埃希菌(52.2%)和肺炎克雷伯菌(26.9%)为主。在肠杆菌中,60.4%产生ESBL, 30.2%对碳青霉烯类耐药。VRE包括所有肠球菌分离物;1例发生PDR鲍曼杆菌。耐药谱与败血症、感染性休克或死亡率之间未发现显著关联。多变量分析发现心力衰竭(优势比[OR] 2.45; 95%可信区间[CI] 1.15-5.21; p = 0.017)和较长的ICU住院时间(OR 1.03 /天;95% CI 1.01-1.05; p = 0.012)是耐多药感染的独立预测因素。结论:我们报告了德黑兰icu中耐多药尿路病原体的惊人负担,强调需要量身定制的经验性治疗指南,加强抗菌药物管理计划和多中心监测,以遏制耐药性并改善患者预后。
{"title":"Prevalence and Resistance Patterns of Uropathogens in Critically Ill Patients at a Tertiary Care Hospital in Tehran: Implications for Antimicrobial Stewardship in Developing Countries.","authors":"Parisa Kianpour, Saba Ranjbarian, Faezeh Azimi Movahed, Sepideh Hamedi, Reza Mourtami, Mohammadamin Qahari, Pejman Pourfakhr, Hamidreza Sharifnia, Mojtaba Mojtahedzadeh, Farhad Najmeddin","doi":"10.1177/10766294251384089","DOIUrl":"https://doi.org/10.1177/10766294251384089","url":null,"abstract":"<p><p><b><i>Background:</i></b> Antimicrobial resistance is a critical global threat in resource-limited settings with underdeveloped laboratory capacity and stewardship programs. Intensive care unit (ICU) patients are at high risk for complicated urinary tract infections (cUTIs) caused by multidrug-resistant (MDR) uropathogens. Local resistance data are essential to guide empirical therapy and design effective stewardship interventions. <b><i>Methods:</i></b> We conducted a retrospective, cross-sectional study (March 2020-December 2022) of 127 adult ICU patients with cUTIs at a tertiary hospital in Tehran, Iran. Urine isolates were identified by standard phenotypic methods, and antimicrobial susceptibility testing (AST) was performed via disk diffusion following Clinical and Laboratory Standards Institute guidelines. Resistance phenotypes-extended-spectrum beta-lactamase (ESBL) production, carbapenem-resistant Enterobacteriaceae, vancomycin-resistant enterococci (VRE), difficult-to-treat <i>Pseudomonas</i>, and pan-drug-resistant (PDR) <i>Acinetobacter baumannii</i>-were defined using current breakpoints. <b><i>Results:</i></b> <i>Escherichia coli</i> (52.2%) and <i>Klebsiella pneumoniae</i> (26.9%) predominated. Among Enterobacterales, 60.4% produced ESBL and 30.2% were carbapenem resistant. VRE comprised all enterococcal isolates; PDR <i>A. baumannii</i> occurred in one case. No significant associations were found between resistance profiles and sepsis, septic shock, or mortality. Multivariable analysis identified heart failure (odds ratio [OR] 2.45; 95% confidence interval [CI] 1.15-5.21; <i>p</i> = 0.017) and longer ICU stay (OR 1.03 per day; 95% CI 1.01-1.05; <i>p</i> = 0.012) as independent predictors of MDR infection. <b><i>Conclusions:</i></b> We report an alarming burden of MDR uropathogens in Tehran ICUs, underscoring the need for tailored empirical-therapy guidelines, enhanced antimicrobial stewardship programs, and multicenter surveillance to curb resistance and improve patient outcomes.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: Carbapenem-resistant Acinetobacter baumannii (CRAB) is an opportunistic infectious agent that can cause bacterial colonization and nosocomial infection. This study aims to explore independent risk factors associated with progression from respiratory colonization to infection among CRAB-colonized patients in the general wards. Methods: We performed a retrospective study among 202 CRAB-colonized patients in the general wards of our hospital between January 2021 and December 2023. We employed both univariate and multivariable logistic regression models to explore factors associated with the progression from colonization to infection. Results: Among 202 CRAB-colonized patients, 66 experienced progression to subsequent infection and 36 died within 28 days. CRAB-colonized patients with subsequent infection had a significantly higher mortality rate (27.27% vs. 13.24%) than patients without infection (p = 0.014). After performing multivariate logistic regression analysis, CRAB-colonized patients with lower albumin (ALB) levels (OR = 0.94, p = 0.029), as well as those receiving antibiotics (OR = 2.49, p = 0.020) or glucocorticoids (OR = 2.49, p = 0.005), were at higher risk of subsequent infection. Furthermore, among patients with CRAB infection developed after colonization, the use of antifungal drugs (OR = 18.06, p = 0.002) and central venous catheter (OR = 10.73, p = 0.002) was the factors that associated with 28-day mortality. Conclusion: Our study analyzed CRAB colonization and infection in general medicine wards. Lower ALB levels and antibiotic/glucocorticoid use were risk factors for infection in colonized patients. Among those developing CR-CRAB infection, antifungal use and central venous catheters were associated with 28-day mortality. These findings can inform preventive and therapeutic guidelines for CRAB infections.
目的:耐碳青霉烯鲍曼不动杆菌(CRAB)是一种机会性感染因子,可引起细菌定植和医院感染。本研究旨在探讨普通病房中螃蟹定植患者从呼吸道定植到感染进展的独立危险因素。方法:对2021年1月至2023年12月在我院普通病房就诊的202例螃蟹定植患者进行回顾性研究。我们采用单变量和多变量逻辑回归模型来探索与从定植到感染进展相关的因素。结果:202例螃蟹定植患者中,66例出现后续感染进展,36例在28天内死亡。随后感染的患者死亡率(27.27% vs. 13.24%)显著高于未感染的患者(p = 0.014)。经多因素logistic回归分析,螃蟹定群中白蛋白(ALB)水平较低的患者(OR = 0.94, p = 0.029)以及接受抗生素(OR = 2.49, p = 0.020)或糖皮质激素(OR = 2.49, p = 0.005)的患者后续感染的风险较高。此外,在定植后发生螃蟹感染的患者中,使用抗真菌药物(OR = 18.06, p = 0.002)和中心静脉导管(OR = 10.73, p = 0.002)是与28天死亡率相关的因素。结论:本研究分析了普通内科病房CRAB的定植和感染情况。较低的ALB水平和抗生素/糖皮质激素的使用是定植患者感染的危险因素。在发生CR-CRAB感染的患者中,使用抗真菌药物和中心静脉导管与28天死亡率相关。这些发现可以为螃蟹感染的预防和治疗提供指导。
{"title":"Risk Factors for Developing Infection Among Patients with Previous Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Respiratory Colonization in the General Wards.","authors":"Guowen Chen, Jianjun Liao, Jinliang Mo, Baojun Guo, Haiming Niu, Miaolian Chen","doi":"10.1177/10766294251382786","DOIUrl":"https://doi.org/10.1177/10766294251382786","url":null,"abstract":"<p><p><b><i>Purpose:</i></b> Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) is an opportunistic infectious agent that can cause bacterial colonization and nosocomial infection. This study aims to explore independent risk factors associated with progression from respiratory colonization to infection among CRAB-colonized patients in the general wards. <b><i>Methods:</i></b> We performed a retrospective study among 202 CRAB-colonized patients in the general wards of our hospital between January 2021 and December 2023. We employed both univariate and multivariable logistic regression models to explore factors associated with the progression from colonization to infection. <b><i>Results:</i></b> Among 202 CRAB-colonized patients, 66 experienced progression to subsequent infection and 36 died within 28 days. CRAB-colonized patients with subsequent infection had a significantly higher mortality rate (27.27% vs. 13.24%) than patients without infection (<i>p</i> = 0.014). After performing multivariate logistic regression analysis, CRAB-colonized patients with lower albumin (ALB) levels (OR = 0.94, <i>p</i> = 0.029), as well as those receiving antibiotics (OR = 2.49, <i>p</i> = 0.020) or glucocorticoids (OR = 2.49, <i>p</i> = 0.005), were at higher risk of subsequent infection. Furthermore, among patients with CRAB infection developed after colonization, the use of antifungal drugs (OR = 18.06, <i>p</i> = 0.002) and central venous catheter (OR = 10.73, <i>p</i> = 0.002) was the factors that associated with 28-day mortality. <b><i>Conclusion:</i></b> Our study analyzed CRAB colonization and infection in general medicine wards. Lower ALB levels and antibiotic/glucocorticoid use were risk factors for infection in colonized patients. Among those developing CR-CRAB infection, antifungal use and central venous catheters were associated with 28-day mortality. These findings can inform preventive and therapeutic guidelines for CRAB infections.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145176772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-22DOI: 10.1177/10766294251380517
Zhou Liu, Chengcheng Ma, Xuan Teng, Kexue Yu, Jiabin Li
This study reports the discovery of a Klebsiella pneumoniae (KPN) strain carrying the blaNDM-1, blaOXA-1, and mcr-9 genes in China for the first time. This strain was isolated from the blood of a 2-year-old pediatric patient with acute lymphoblastic leukemia and sepsis. The strain exhibited high resistance to various antibiotics, including β-lactams, carbapenems, and ceftazidime-avibactam. Through whole-genome sequencing and comparative genomic analysis, we found that these resistance genes coexisted on the transferable IncHI2/IncHI2A-type plasmid pK708696_1, which showed high similarity to plasmid pK710429_2 from strain KPN710429 previously identified in our hospital, indicating their potential for rapid spread through horizontal gene transfer. We also performed conjugation experiments to verify the transferability of the plasmid. The results show that the resistance of this strain to traditional antibiotics significantly limited clinical treatment options, thereby posing a serious threat, especially for pediatric leukemia patients with compromised immune systems. This study provides important scientific evidence and new therapeutic approaches for combating carbapenem-resistant Klebsiella pneumoniae infections and highlights the urgency of developing new antibiotics and alternative therapies.
{"title":"Emergence of Pediatric Sepsis Caused by a <i>Klebsiella pneumoniae</i> Strain Coharboring <i>bla</i><sub>NDM-1</sub>, <i>bla</i><sub>OXA-1</sub>, and <i>Mcr-9</i> in China.","authors":"Zhou Liu, Chengcheng Ma, Xuan Teng, Kexue Yu, Jiabin Li","doi":"10.1177/10766294251380517","DOIUrl":"https://doi.org/10.1177/10766294251380517","url":null,"abstract":"<p><p>This study reports the discovery of a <i>Klebsiella pneumoniae</i> (KPN) strain carrying the <i>bla</i><sub>NDM-1</sub>, <i>bla</i><sub>OXA-1</sub>, and <i>mcr-9</i> genes in China for the first time. This strain was isolated from the blood of a 2-year-old pediatric patient with acute lymphoblastic leukemia and sepsis. The strain exhibited high resistance to various antibiotics, including β-lactams, carbapenems, and ceftazidime-avibactam. Through whole-genome sequencing and comparative genomic analysis, we found that these resistance genes coexisted on the transferable IncHI2/IncHI2A-type plasmid pK708696_1, which showed high similarity to plasmid pK710429_2 from strain KPN710429 previously identified in our hospital, indicating their potential for rapid spread through horizontal gene transfer. We also performed conjugation experiments to verify the transferability of the plasmid. The results show that the resistance of this strain to traditional antibiotics significantly limited clinical treatment options, thereby posing a serious threat, especially for pediatric leukemia patients with compromised immune systems. This study provides important scientific evidence and new therapeutic approaches for combating carbapenem-resistant <i>Klebsiella pneumoniae</i> infections and highlights the urgency of developing new antibiotics and alternative therapies.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Antimicrobial resistance (AMR) is a growing global threat that complicates the treatment of infectious diseases, including plague. Yersinia pestis, the causative agent of plague, remains a serious public health concern in natural foci, such as those in Kazakhstan, where approximately 40% of the territory is plague-endemic. Despite the last reported human case in 2003, data on antibiotic resistance among Y. pestis isolates from these foci, especially historical ones, remain limited. Materials and Methods: A total of 75 Y. pestis strains were examined, including 61 isolates obtained from patients and deceased individuals during epidemic outbreaks (1926-2003) and 14 isolates from carriers and vectors in natural plague foci. Taxonomic identification was conducted using the Vitek 2 Compact 30 system. Antibiotic susceptibility was assessed by Kirby-Bauer disk diffusion and E-test methods. Extended-spectrum β-lactam (ESBL) activity was evaluated phenotypically, and resistance genes to glycopeptides and β-lactams were screened by real-time polymerase chain reaction (RT-PCR) using the BacResista GLA Detection Kit. Results: All isolates showed complete susceptibility (100%) to β-lactams, tetracyclines, aminoglycosides, amphenicols, glycopeptides, lincosamides, and quinolones. The overall susceptibility rate across antibiotic classes was 97.5%. Macrolides exhibited low activity (0.0-58.0%), consistent with known limitations against Gram-negative bacteria. No ESBL production was detected phenotypically, and RT-PCR screening found no resistance genes (vanA/B, mecA, tem, ctx-M-1, shv, oxa, imp, kpc, ndm, etc.). Conclusions: These findings confirm a lack of resistance to key antibiotic classes in historical Y. pestis isolates from Kazakhstan. Despite the absence of recent human cases, ongoing epizootics among wild animals highlight a persistent risk of transmission. This study, conducted for the first time in Kazakhstan, has important implications for public health preparedness and clinical management during plague outbreaks.
{"title":"Antibiotic Susceptibility Screening and Search for Resistance Genes in <i>Yersinia pestis</i> Clinical Isolates from Plague Outbreaks in Natural Foci of Kazakhstan (1926-2003).","authors":"Zyat Abdel, Zauresh Zhumadilova, Raikhan Mussagalieva, Aigul Abdirassilova, Altyn Rysbekova, Svetlana Issaeva, Bolatbek Baitursyn, Beck Abdeliyev, Dinmukhammed Otebay, Ardak Jumagaziyeva, Bauyrzhan Toizhanov, Nurbol Shakiyev","doi":"10.1177/10766294251362277","DOIUrl":"10.1177/10766294251362277","url":null,"abstract":"<p><p><b><i>Background:</i></b> Antimicrobial resistance (AMR) is a growing global threat that complicates the treatment of infectious diseases, including plague. <i>Yersinia pestis</i>, the causative agent of plague, remains a serious public health concern in natural foci, such as those in Kazakhstan, where approximately 40% of the territory is plague-endemic. Despite the last reported human case in 2003, data on antibiotic resistance among <i>Y. pestis</i> isolates from these foci, especially historical ones, remain limited. <b><i>Materials and Methods:</i></b> A total of 75 <i>Y. pestis</i> strains were examined, including 61 isolates obtained from patients and deceased individuals during epidemic outbreaks (1926-2003) and 14 isolates from carriers and vectors in natural plague foci. Taxonomic identification was conducted using the Vitek 2 Compact 30 system. Antibiotic susceptibility was assessed by Kirby-Bauer disk diffusion and E-test methods. Extended-spectrum β-lactam (ESBL) activity was evaluated phenotypically, and resistance genes to glycopeptides and β-lactams were screened by real-time polymerase chain reaction (RT-PCR) using the BacResista GLA Detection Kit. <b><i>Results:</i></b> All isolates showed complete susceptibility (100%) to β-lactams, tetracyclines, aminoglycosides, amphenicols, glycopeptides, lincosamides, and quinolones. The overall susceptibility rate across antibiotic classes was 97.5%. Macrolides exhibited low activity (0.0-58.0%), consistent with known limitations against Gram-negative bacteria. No ESBL production was detected phenotypically, and RT-PCR screening found no resistance genes (vanA/B, mecA, tem, ctx-M-1, shv, oxa, imp, kpc, ndm, etc.). <b><i>Conclusions:</i></b> These findings confirm a lack of resistance to key antibiotic classes in historical <i>Y. pestis</i> isolates from Kazakhstan. Despite the absence of recent human cases, ongoing epizootics among wild animals highlight a persistent risk of transmission. This study, conducted for the first time in Kazakhstan, has important implications for public health preparedness and clinical management during plague outbreaks.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"287-299"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144732351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A notable increase in the incidence of vancomycin-resistant Enterococcus faecium (VREfm) was observed at a hospital in Guangzhou, China, during 2022-2023. We conducted a retrospective cross-sectional study from January 1, 2022, to August 31, 2023, to investigate the clinical and genomic characteristics of VREfm. Clinical data were extracted from electronic medical records, and infection control measures were reviewed from the relevant department. VREfm confirmation was performed using antimicrobial susceptibility testing. Genomic characteristics were analyzed via the whole-genome sequencing. The prevalence of VREfm among E. faecium isolates rose significantly from 13.3% (10/75) in 2022 to 26.4% (40/151) by August 2023 (p < 0.001). Concurrently, usage of third-generation cephalosporins increased by 8.4% (22.47 to 24.36 defined daily doses per 100 patient days), carbapenems by 34% (51.47-68.97), and vancomycin by 18% (21.15-24.97) (all p ≤ 0.001). Molecular analysis revealed ST80/CC17 (78%, 39/50) as the dominant clone, carrying vanA and virulence genes (scm, acm, and fss3), suggesting clonal expansion of a lineage rarely reported in Guangzhou. Our study documented an outbreak of ST80/CC17 vanA-positive VREfm, characterized by virulence genes (scm, acm, and fss3) and clonal dominance (78%, 39/50). The temporal association between reduced sodium hypochlorite disinfection (2.7-fold decline, p = 0.002), increased antibiotic selective pressure, and pathogen transmission highlights multifactorial drivers of this epidemic. These findings underscore the complex multifactorial nature of pathogen transmission, including the role of antibiotic use, infection control measures, and environmental factors in the spread of multidrug-resistant clones. Strengthened infection control strategies-integrating targeted disinfection, antibiotic stewardship, and genomic surveillance-are imperative to curb the spread of such multidrug-resistant clones.
{"title":"An Outbreak of ST80 Vancomycin-Resistant <i>Enterococcus faecium</i> in a Hospital in Guangzhou, China: Clinical and Genomic Epidemiology Study from 2022 to 2023.","authors":"Yawen Deng, Xiaoying Xie, Baiji Chen, Zhixan Zhang, Jiaoni Lan, Yi Luan, Guanhua Rao, Peng Han, Chaohui Duan","doi":"10.1177/10766294251361345","DOIUrl":"10.1177/10766294251361345","url":null,"abstract":"<p><p>A notable increase in the incidence of vancomycin-resistant <i>Enterococcus faecium</i> (VREfm) was observed at a hospital in Guangzhou, China, during 2022-2023. We conducted a retrospective cross-sectional study from January 1, 2022, to August 31, 2023, to investigate the clinical and genomic characteristics of VREfm. Clinical data were extracted from electronic medical records, and infection control measures were reviewed from the relevant department. VREfm confirmation was performed using antimicrobial susceptibility testing. Genomic characteristics were analyzed via the whole-genome sequencing. The prevalence of VREfm among <i>E. faecium</i> isolates rose significantly from 13.3% (10/75) in 2022 to 26.4% (40/151) by August 2023 (<i>p</i> < 0.001). Concurrently, usage of third-generation cephalosporins increased by 8.4% (22.47 to 24.36 defined daily doses per 100 patient days), carbapenems by 34% (51.47-68.97), and vancomycin by 18% (21.15-24.97) (all <i>p</i> ≤ 0.001). Molecular analysis revealed ST80/CC17 (78%, 39/50) as the dominant clone, carrying <i>vanA</i> and virulence genes (<i>scm</i>, <i>acm,</i> and <i>fss3</i>), suggesting clonal expansion of a lineage rarely reported in Guangzhou. Our study documented an outbreak of ST80/CC17 <i>vanA</i>-positive VREfm, characterized by virulence genes (<i>scm</i>, <i>acm,</i> and <i>fss3</i>) and clonal dominance (78%, 39/50). The temporal association between reduced sodium hypochlorite disinfection (2.7-fold decline, <i>p</i> = 0.002), increased antibiotic selective pressure, and pathogen transmission highlights multifactorial drivers of this epidemic. These findings underscore the complex multifactorial nature of pathogen transmission, including the role of antibiotic use, infection control measures, and environmental factors in the spread of multidrug-resistant clones. Strengthened infection control strategies-integrating targeted disinfection, antibiotic stewardship, and genomic surveillance-are imperative to curb the spread of such multidrug-resistant clones.</p>","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"269-278"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144715148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-07-28DOI: 10.1177/10766294251364752
Gherard Batisti Biffignandi, Giacomo Maria Paganotti, Pearl Ntshonga, Jonathan P Strysko, Paolo Gaibani
{"title":"<i>Letter:</i> Complete Genome Sequence of <i>Klebsiella pneumoniae</i> ST15 Carrying <i>bla</i><sub>NDM-1</sub> and <i>bla</i><sub>CTX-M-15</sub> from Botswana, Africa.","authors":"Gherard Batisti Biffignandi, Giacomo Maria Paganotti, Pearl Ntshonga, Jonathan P Strysko, Paolo Gaibani","doi":"10.1177/10766294251364752","DOIUrl":"10.1177/10766294251364752","url":null,"abstract":"","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"300-301"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144732350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}